WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has announced a cooperation memorandum of understanding (MOU) with South Korean firm Celltrion Inc. (KRX: 068270) to provide comprehensive services for the development and manufacturing of bioconjugated drugs, including antibody drug conjugates (ADCs).
According to the agreement, Celltrion will engage WuXi XDC as the primary service provider to offer services ranging from process development to GMP production for each comprehensive project on a global scale. WuXi XDC will become a strategic service partner, supporting the advancement of Celltrion’s innovative pipeline by providing end-to-end services from process development to one-stop GMP production, enabling Celltrion to expedite the high-quality development of its ADC pipelines.- Flcube.com
